<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353846</url>
  </required_header>
  <id_info>
    <org_study_id>0901-C-055-MF</org_study_id>
    <nct_id>NCT01353846</nct_id>
  </id_info>
  <brief_title>Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients</brief_title>
  <official_title>Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the natural cycle (without any medication) with the
      well-established artificial cycle in an egg donation program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oocyte donation is an assisted reproduction technique well established. In patients with
      ovarian function, it is necessary to synchronize the cycle of the egg donor with the
      recipient, usually through endometrial preparation of the recipient by artificial cycle, by
      administering a GnRH agonist on day 21 of cycle and then administered increasing doses of
      estrogen therapy to achieve adequate endometrial thickness.

      The necessity of synchronization between donors and recipient, has made possible not
      routinely the natural cycle for oocyte donation.

      The investigators have recently introduced oocyte vitrification and it allows us to plan the
      egg donation in a different way. Now the investigators can previously cryopreserved donor
      oocytes and at the time that the investigators have a compatible receiver, then, plan the
      donation In this study it will be possible compare the results of oocyte donation cycles in
      terms of pregnancy rate, implantation and liveborn, depending on whether the recipient has
      made an artificial cycle of preparation endometrial or a natural cycle.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preparation and treatment for Assisted Human Reproduction procedures and in the case opf pregnancy, follow up.</measure>
    <time_frame>12 months</time_frame>
    <description>Outcome of the study is measured by the pregnancy rates after IVF treatments of both arms.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Natural cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.
Natural micronized progesterone, 400 mg/12 hours vaginal administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observation natural cycle</intervention_name>
    <description>The patients natural reproductive cycle will be observed and compared to the second arm.</description>
    <arm_group_label>Natural cycle</arm_group_label>
    <other_name>Control group with natural menstration cycle.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agonist GnRH; estradiol Valerate; progesterone</intervention_name>
    <description>Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration</description>
    <arm_group_label>Artificial cycle</arm_group_label>
    <other_name>Decapeptyl (IPSEN)3.75 mg.</other_name>
    <other_name>Progynova 1 mg (Bayer Schering Farma)</other_name>
    <other_name>Natural micronized progesterone 400 mg/12 hours</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertile females with preserved gonadal function

          -  ages 18 - 44 years old included

          -  first oocyte donation cycle

        Exclusion Criteria:

          -  BMI: &gt; 28

          -  recurrent miscarriages (3 or more)

          -  recurrent of implantation failure

          -  severe male factor

          -  important miomas

          -  &gt; 44 years old

          -  Problems with the drugs used in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dra. Pilar Alamá, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>IVI Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dra. Pilar Alamá</last_name>
    <phone>+34963050900</phone>
    <email>pilar.alama@ivi.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leslie Atkinson</last_name>
    <phone>+34963050900</phone>
    <email>leslie.atkinson@ivi.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Atkinson, MA</last_name>
      <phone>+34963050900</phone>
      <email>leslie.atkinson@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Marcos Ferrando, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>March 30, 2012</last_update_submitted>
  <last_update_submitted_qc>March 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dra. Pilar Alamá</name_title>
    <organization>IVI Valencia</organization>
  </responsible_party>
  <keyword>oocyte donation program</keyword>
  <keyword>natural cycle</keyword>
  <keyword>hormone replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

